Tagged with R&D

Switzerland Dr. Othmar Pfannes, founder and CEO of Genedata, a bioinformatics company headquartered in Switzerland delivering enterprise software, data analysis consulting, and business-process analysis services to the life sciences community, reveals some insights into Genedata’s business strategy and how ultimately their mission is to contribute to reducing the costs of drug…

Switzerland Walter Steinlin describes the Federal Commission of Technology and Innovation as a catalyst for turning research into innovation. Based in Bern, Switzerland, the commission funds research institutes in corporate projects, and provides mentorship and coaching support for start-ups. Could you give our international audience an overview of the Federal Commission…

Research Dr. Thomas Coffman, Dean at Duke-NUS Medical School (Duke-NUS), explains how Duke-NUS has effectively disrupted medical education since the establishment of this unique collaboration 11 years ago. Can you introduce to our international readers the underlying aspirations behind the creation of this partnership between Duke University and NUS as well…

Pharma Actelion’s global CEO and co-founder, Dr Jean-Paul Clozel, discusses diversifying the company’s portfolio, prioritizing internal research over inorganic acquisitions, and retaining a spirit of independence and innovation during a period of rapid growth.   2015 was a fantastic year for the company, the best yet, passing the USD two billion…

R&D Gerardo Cárdenas Vogel, CEO of Innovare R&D, on transforming the company’s business model to benefit from drug development opportunities, Mexico as a world-class clinical trial destination, and new, innovative treatments as part of their partnership with the French biotech company LFB. When our colleagues met with you in February 2015,…

Innovation Professor Mark Ferguson, Director General of Science Foundation Ireland and Chief Scientific Advisor to the Government of Ireland, highlights Ireland’s recent spectacular success in fostering research and innovation; the government’s strategy to further promote Irish science, Innovation 2020; the priority of building academia-industry partnerships; and his mission to turn Ireland…

Research NIBRT’s projects director discusses the new ‘Biologic’ center for biologics research, business development, training, and commercializing the organisation’s extensive research capabilities. As Projects Director, you are responsible for driving NIBRT’s growth and development, in terms of both research and bioprocessing training. What’s the most exciting opportunity that NIBRT is currently working on?…

Pharma Tuomo Pätsi, President of the EMEA region for Celgene, talks about marking the tenth anniversary of Switzerland as Celgene´s EMEA headquarters; reveals how their workforce has increased from a handful of individuals in 2006 to 700 in Switzerland and 2,300 across Europe today; and how Celgene’s continuous R&D investment distinguishes…

Switzerland Prof. Dr. med. Adriano Aguzzi provides insight on the past, present, and future of prion and antibody therapy research in Switzerland. The Institute of Neuropathology works closely with the University Hospital of Zurich to conduct their research. He also touches on translating research to industry and his spinoff ImmunoQure, which…

Health Professor Jürg Utzinger of the Swiss Tropical and Public Health Institute (Swiss TPH) emphasizes the importance of partnerships and sharing information for improving population health locally, nationally, and internationally. He comments on Swiss innovation, the clinical trials conducted at Swiss TPH, and the current publicity around the Zika virus.   You…

Pharma This map shows the overall contribution of the pharmaceutical industry to the French economy, including number of employees by region, investment stats, and information on private sector research. Click here to download the latest free pharma report on France.

Pharma Teodoro Padilla, Executive Director at the Pharmaceutical and Healthcare Association of the Philippines, and Reiner Gloor, Advisor and Honorary Member, discuss the current objectives and goals of the association, how they are adapting to recent changes in the country’s healthcare landscape, and the impact of the rise of generics. To begin, could…